drugset / Trial / NCT04982354
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.
Timeline
- Start
- 2022-07-05
- Primary completion
- 2031-08-01
- Completion
- 2032-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | — | — |
| Subject | Midostaurin | Small molecule | 50 mg | — |
| Background | Busulfan | Small molecule | 0.8 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | Melphalan | Small molecule | 70 mg/m2 | Intravenous |